Parametric survival modeling from FIBRONEER-IPF projected median survival of 3.7 years on placebo versus 5.8 and 9.1 years with nerandomilast 9 mg and 18 mg monotherapy. Background nintedanib ...

Implementing Early Detection in CRM Syndrome,’ the expert nephrologist explored the following questions: What role do ...

FDA approval brings Enhertu into early breast cancer treatment, boosting response before surgery and cutting recurrence risk ...

Efficacy and Safety of Sotatercept in Patients With Pulmonary Arterial Hypertension (PAH) Associated With Connective Tissue ...

Manhattan cordon pricing south of 60th Street reduced traffic volumes and increased bus use, with hypothesized local/regional ...

PASSAGE study data showed tezepelumab improved asthma outcomes across diverse, underrepresented patient populations. Data presented at the American Thoracic Society 2026 International Conference in ...

Inverse-probability reweighting of NHANES 1988–1991 to 2021–2023 demographics projected 5.3 million US adults with ASCVD and ...

Formal adoption of PMOS replaces a cyst-centric label with terminology capturing endocrine, metabolic, and ovarian ...

Global stroke incidence and prevalence continue rising alongside high, underrecognized OSA prevalence and rapidly expanding diabetes burden, with substantial bidirectional comorbidity in type 2 ...

Communication gaps persisted despite shared decision-making norms, with limited patient-perceived comprehension and ...

Medication adherence is a key to improving outcomes, reducing costs, and strengthens the patient experience, making it an ...

Preterm birth is a lifelong cardiopulmonary risk marker, with markedly higher cardiovascular disease and heart failure risk ...